Published in J Clin Oncol on May 01, 2001
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol (2009) 2.56
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer (2003) 1.46
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer (2010) 1.23
Whole tumor antigen vaccines. Semin Immunol (2010) 1.19
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother (2008) 1.18
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer (2006) 1.06
Rosemary (Rosmarinus officinalis) extract modulates CHOP/GADD153 to promote androgen receptor degradation and decreases xenograft tumor growth. PLoS One (2014) 0.94
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm (2006) 0.90
Is there a role for chemotherapy in prostate cancer? Br J Cancer (2004) 0.89
Chemotherapy for androgen-independent prostate cancer. World J Urol (2005) 0.89
Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl (2014) 0.88
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer (2008) 0.88
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Cancer Res (2011) 0.87
Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? Cancer Ther (2007) 0.87
Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87
Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm (2011) 0.85
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer (2007) 0.84
Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int (2012) 0.83
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs (2009) 0.83
Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer (2002) 0.81
The role of the urologist in treating patients with hormone-refractory prostate cancer. Rev Urol (2003) 0.81
Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol (2003) 0.81
Concurrent chemoradiation for high-risk prostate cancer. World J Clin Oncol (2015) 0.81
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest New Drugs (2007) 0.80
[Chemotherapy for prostate cancer]. Wien Klin Wochenschr (2008) 0.79
Docetaxel for the treatment of hormone-refractory prostate cancer. Rev Urol (2003) 0.79
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. Int J Clin Oncol (2011) 0.78
Innovative therapies for prostate cancer treatment. Rev Urol (2003) 0.78
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol (2003) 0.78
The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer. Biomed Res Int (2015) 0.77
Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat. Oncol Lett (2011) 0.77
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol (2003) 0.76
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol (2008) 0.75
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol (2009) 0.75
Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Rev Urol (2003) 0.75
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. Br J Cancer (2007) 0.75
Rationale for the Radiation Therapy Oncology Group Study RTOG P-0014. Rev Urol (2003) 0.75
Prostate cancer update: advanced disease. Rev Urol (2003) 0.75
Chemotherapy for hormone-resistant prostate cancer: Where are we today? Indian J Urol (2007) 0.75
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
E-MSD: the European Bioinformatics Institute Macromolecular Structure Database. Nucleic Acids Res (2003) 7.79
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med (1998) 5.20
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
Low male partner participation in antenatal HIV counselling and testing in northern Tanzania: implications for preventive programs. AIDS Care (2008) 3.58
E-MSD: an integrated data resource for bioinformatics. Nucleic Acids Res (2004) 3.43
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
Predicting difficult endotracheal intubation in surgical patients scheduled for general anesthesia: a prospective blind study. Anesth Analg (1995) 2.45
E-MSD: improving data deposition and structure quality. Nucleic Acids Res (2006) 2.41
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Infliximab for refractory ulcerative colitis. Am J Gastroenterol (2001) 2.26
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol (2001) 2.21
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 2.18
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA (1991) 2.12
Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet (1981) 2.06
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol (1997) 1.99
The cloning and nucleotide sequence of cDNA for an amplified glutamine synthetase gene from the Chinese hamster. Nucleic Acids Res (1986) 1.95
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res (2000) 1.93
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Prevalence of depression and diabetes: a population-based study from rural Bangladesh. Diabet Med (2007) 1.84
Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol (1999) 1.81
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst (1994) 1.69
Presumptive evidence for Blastocystis hominis as a cause of colitis. Arch Intern Med (1988) 1.64
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res (1997) 1.62
A systematic review of the evidence for telemedicine in burn care: with a UK perspective. Burns (2011) 1.60
National survey of the management of eye emergencies in the accident and emergency departments by senior house officers: 10 years on--has anything changed? Emerg Med J (2008) 1.58
Front-line management of pulmonary tuberculosis: an analysis of tuberculosis and treatment practices in urban Sindh, Pakistan. Tuber Lung Dis (1996) 1.48
Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med (1981) 1.47
The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res (1993) 1.45
A study of breathing pattern and ventilation in newborn infants and adult subjects. Acta Paediatr (2000) 1.45
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer (1993) 1.44
Can tailored interventions increase mammography use among HMO women? Am J Prev Med (2000) 1.42
In vitro effects of sildenafil and phentolamine, drugs used for erectile dysfunction, on human sperm motility. Am J Obstet Gynecol (2000) 1.42
Acute pulmonary toxicity after low-dose amiodarone therapy. Ann Thorac Surg (2001) 1.42
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst (1988) 1.41
Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol (1994) 1.40
Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases. J Urol (1994) 1.39
Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res (2001) 1.39
Effects of cardiac glycosides on atrial contractile dysfunction after short-term atrial fibrillation. Chest (2000) 1.39
Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin Proc (1997) 1.38
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res (1983) 1.38
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr (1997) 1.37
Cardiac metastases from soft-tissue sarcomas. J Clin Oncol (1986) 1.36
Patients' choice of treatment in stage D prostate cancer. Urology (1989) 1.34
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer (1985) 1.31
Deficiencies in current childhood immunization indicators. Public Health Rep (1998) 1.31
Renal pelvic cancer: a review of 611 patients treated in Illinois 1975-1985. Cancer Incidence and End Results Committee. Urology (1992) 1.30
Perception of consanguineous marriages and their genetic effects among a sample of couples from Beirut. Am J Med Genet (1986) 1.29
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol (2000) 1.28
Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol (2010) 1.27
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol (2000) 1.26
HIV seroprevalence and its associations with the other reproductive tract infections in asymptomatic women in Harare, Zimbabwe. Int J STD AIDS (2001) 1.26
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer (1998) 1.25
Breast cancer screening behaviors and attitudes in three racial/ethnic groups. Cancer (1992) 1.24
Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 1.21
Sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) gene silencing and remodeling of the Ca2+ signaling mechanism in cardiac myocytes. Proc Natl Acad Sci U S A (2004) 1.21
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol (1998) 1.20
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19
The short-term impact of tailored mammography decision-making interventions. Patient Educ Couns (2001) 1.18
Pulled elbow--not the effect of hypermobility of joints. Injury (1995) 1.18
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res (2001) 1.18
Malignant mesothelioma. The University of Minnesota experience. Cancer (1984) 1.17
Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol (1987) 1.16
The prevalence, classification and treatment of mental disorders among attenders of native faith healers in rural Pakistan. Soc Psychiatry Psychiatr Epidemiol (2000) 1.15
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol (1999) 1.15
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol (2005) 1.14
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol (2001) 1.13
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res (1999) 1.11
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol (1997) 1.11
Does anatomy explain the origin of a leak after sleeve gastrectomy. Obes Surg (2015) 1.11
Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. J Gen Virol (1997) 1.11
Women's interest in chemoprevention for breast cancer. Arch Intern Med (2001) 1.10
Validation of the surveillance system for tuberculosis in Botswana. Int J Tuberc Lung Dis (2000) 1.10
One hundred thirteen men with hormone-refractory prostate cancer died today. J Clin Oncol (1996) 1.10
Letter to the editor: a multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg (2013) 1.10
Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol (1994) 1.10
Factors associated with perceived risk of breast cancer among women attending a screening program. Breast Cancer Res Treat (1993) 1.08
Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res (2001) 1.08
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol (1988) 1.08
Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev (1996) 1.07
Precautionary note for use of bisulfite in pharmaceutical formulations. J Pharm Sci (1977) 1.07
Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. Cancer Res (1995) 1.07